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Abstract
In several murine models of transplantation, the “cross-dressing” of recipient antigen pre-
senting cells (APCs) with intact donor major histocompatibility complex (MHC) derived 
from allograft-released small extracellular vesicles (sEVs) has been recently described 
as a key mechanism in eliciting and sustaining alloimmune responses. Investigation 
of these processes in clinical organ transplantation has, however, been hampered by 
the lack of sensitivity of conventional instruments and assays. We have employed ad-
vanced imaging flow cytometry (iFCM) to explore the kinetics of allograft sEV release 
and the extent to which donor sEVs might induce cross-dressing following liver and 
kidney transplantation. We report for the first time that recipient APC cross-dressing 
can be transiently detected in the circulation shortly after liver, but not kidney, trans-
plantation in association with the release of HLA-bearing allograft-derived sEVs. In liver 
transplant recipients the majority of circulating cells exhibiting donor HLA are indeed 
cross-dressed cells and not passenger leukocytes. In keeping with experimental animal 
data, the downstream functional consequences of the transfer of circulating sEVs har-
vested from human transplant recipients varies depending on the type of transplant and 
time posttransplant. sEVs released shortly after liver, but not kidney, transplantation 
exhibit immunoinhibitory effects that could influence liver allograft immunogenicity.
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1  | INTRODUC TION
Induction of immune responses to major histocompatibility complex 
(MHC) mismatched allografts has been traditionally considered to 
result from the migration of graft-derived antigen presenting cells 
(APCs), or “passenger leukocytes,” to secondary lymphoid organs 
where they directly present intact donor MHC molecules to recip-
ient alloreactive T cells. This model has recently been called into 
question, with mounting data from both vascularized and non-vas-
cularized animal transplant models showing that in the early post-
transplant period few if any such passenger donor leukocytes are 
found in secondary lymphoid organs.1-3 In contrast, within hours 
of transplantation, a much larger number of recipient APCs in the 
graft-draining lymph nodes or spleen carry donor-type MHC mole-
cules on their surface.1,3,4 The transfer of intact donor MHC to re-
cipient APCs is known as “cross-dressing” and is partly mediated by 
allograft-derived extracellular vesicles (EVs) released into the circu-
lation.1,3 EVs are nanosized membranous particles released by most 
cell subsets, including graft parenchymal cells, endothelium, and 
passenger leukocytes. Owing to their small size and their capacity to 
transport a variety of biomolecules, they function as key mediators 
of intercellular communication, relayed across a spectrum of bioflu-
ids and tissue types. Among their surface protein cargo, EVs carry in-
tact MHC and peptide/MHC complexes, which confers to them the 
capacity to activate T cells.5-7 Although their direct allostimulatory 
capacity is weak and requires high EV concentrations,5,6,8 the po-
tential for such peptide/MHC complexes to elicit alloresponses can 
be markedly enhanced if transferred to APCs.8-12 Among the range 
of EV subtypes, those most widely reported to play a key part in the 
cross-dressing of APCs are “exosomes,” small EVs (50-200 nm) of 
endosomal origin, exhibiting characteristic morphological features, 
and thought to bear a characteristic complement of tetraspanin 
protein surface markers. In recent years, it has become evident that 
commonly employed exosome isolation techniques in fact isolate 
heterogenous populations of small EVs with the size characteristics 
of exosomes, not necessarily of endosomal origin. In the interests 
of definitional accuracy, such isolates are increasingly referred to as 
small EVs (sEVs). Though no single marker is known to uniquely iden-
tify the exosomal fraction of such isolates, proteomic analyses of 
sEV subpopulations have identified CD63 as a candidate – thus sEVs 
bearing CD63 are putatively designated exosomes.13-15
In most experimental transplant models, allo-MHC cross-dress-
ing has been shown to be a highly immunogenic phenomenon. The 
capacity of cross-dressed dendritic cells (DCs) to elicit alloreactive T 
cell responses in vitro was first described by Herrera and colleagues16 
and subsequently confirmed in vivo by the same group in a mouse 
skin transplant model.4 More recently, Benichou and colleagues 
showed that injection into naïve mice of allogeneic EVs or of recipi-
ent cells cross-dressed in vitro with donor EVs was sufficient to elicit 
a donor-specific inflammatory alloresponse in vivo.3 Furthermore, 
Morelli and colleagues demonstrated that upon acquiring donor 
EVs, recipient DCs became activated, stimulated alloreactive T cells, 
and promoted allograft rejection. The immunogenicity of allo-MHC 
cross-dressed DCs is not restricted to secondary lymphoid organs 
and is also apparent in the allograft itself. Thus, in rodent models 
of islet and kidney transplantation, rejection was preceded by the 
engagement of effector T cells with cross-dressed graft-infiltrating 
host DCs.17 However, in contrast to these observations, in a model 
of spontaneous tolerance following MHC-mismatched murine liver 
transplantation, recipient intrahepatic DCs cross-dressed with donor 
sEVs markedly suppressed alloreactive host T cell responses,18 sug-
gesting that the outcome of recipient APC cross-dressing may vary 
depending on the type of allograft.
The characterization of the kinetics of allograft sEV release and 
elucidation of the extent to which donor sEVs induce recipient APC 
cross-dressing following clinical organ transplantation have been 
hampered by the lack of sensitivity of conventional flow cytometric 
instruments. We recently developed a method by which circulating 
small EVs, including exosomes, can be characterized and quantified 
using advanced imaging flow cytometry (iFCM).13 We report here 
the results of applying this technique to investigate the kinetics of 
donor-derived, CD63 bearing, sEV release in the clinical contexts of 
liver and kidney transplantation and describe for the first time the 
development of recipient APC cross-dressing in clinical transplanta-
tion. Our findings confirm that following liver, but not kidney, trans-
plantation, the majority of circulating cells exhibiting donor MHC are 
cross-dressed cells and not passenger leukocytes. This is, however, 
a transient phenomenon, which is no longer detectable beyond the 
first weeks posttransplant regardless of the liver allograft status.
2  | MATERIAL S AND METHODS
2.1 | Study population and design
The study was approved by the North of Scotland Research Ethics 
Committee (REC Ref: 15/NS/0062) and all participants provided 
written informed consent. Peripheral blood samples were collected 
from liver (LTx) and kidney (KTx) transplant recipients immediately 
before transplantation and at posttransplant days 1, 4, 10, and 30. 
Additional sequential peripheral blood specimens were collected 
from stable LTx >3 years posttransplant who experienced an episode 
of histologically confirmed rejection following attempted complete 
immunosuppression withdrawal (clinicaltrials.gov, NCT02498977). 
All participants were human leukocyte antigen (HLA) genotyped by 
polymerase chain reaction sequence-specific oligonucleotide probes 
(PCR-SSOP, Luminex, Austin, TX) at the Clinical Transplantation 
Laboratory at Guy's Hospital London.
2.2 | Circulating sEV and peripheral blood 
mononuclear cell (PBMC) isolation
Peripheral blood was collected following standard procedures that 
minimize contamination by platelets and platelet-derived vesicles.19 
Following cubital vein venepuncture, 3 mL of blood was discarded 
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before collection of 9 mL into BD Vacutainer® K3-EDTA-coated collec-
tion tubes (Becton, Dickinson, Franklin Lakes, NJ). Tubes were inverted 
gently 5 times and blood was allowed to sit at room temperature for 
30 minutes. Whole blood was centrifuged at 400 g (Heraeus Megafuge 
40R with 195 mm 7500-3180 rotor, ThermoFisher Scientific, Waltham, 
MA) for 10 minutes at 20°C to remove cells. The plasma layer was col-
lected and centrifuged again at 5000 g for 10 minutes at 20°C. The re-
sulting platelet-poor plasma (PPP) was aliquoted and stored at −80°C. 
small EVs (sEVs) were isolated from PPP by size-exclusion chromatog-
raphy (SEC) using CellGS Exo-SpinTM Mini Columns according to manu-
facturer's instructions, and as previously validated.13,20,21 Specifically, 
PPP was thawed and centrifuged at 16 000 g for 30 minutes (Sorval 
Legend Micro 21R equipped with 7500-3424 rotor, ThermoFisher 
Scientific) to remove large particles and cell fragments, and superna-
tant transferred to a new micrcentrifuge tube and set on ice. CellGS 
columns were equilibrated 15 minutes prior to use. Using a micropi-
pette, the preservative buffer on top of the column was discarded, the 
outlet plug removed, and 200 μL of 0.22 μm-filtered phosphate-buff-
ered saline (fPBS) was added to the top of the column. The column was 
then centrifuged for 10 seconds at 50 g (Centrifuge 5430 R, equipped 
with FA-45-24-11-HS rotor, Eppendorf, Hamburg, Germany). 0.1 mL 
PPP was applied to the column and centrifuged at 50 g for 60 seconds. 
The column was then transferred to a new 1.5 mL collection tube, 
200 μL fPBS applied to the top, and elution of sEVs performed by a 
final centrifugation step at 50 g for 60 seconds. Confirmation of sEV 
isolation was performed as previously described (Figure S1).13 Eluate 
volume was topped up to 200 μL if necessary with fPBS, aliquoted, and 
stored at −80°C. Peripheral blood mononuclear cell (PBMC) isolation 
was performed by Ficoll-Paque (GE Healthcare, Danderyd, Sweden) 
density-gradient sedimentation and stored in liquid nitrogen.
2.3 | Circulating sEV analyses by ImageStreamx
Multispectral imaging flow cytometric acquisition of sEVs was per-
formed using Amnis ImageStreamx MKII (ISx, EMD Millipore, Seattle, 
WA) as previously described.13 ISx fluidics were set at low speed, sen-
sitivity set to high, magnification at 60x, core size 7 μm, and the “Hide 
Beads” option unchecked before every acquisition in order to visualize 
speed beads in analyses. The ISx was equipped with the following lasers 
run at maximal power to ensure maximal sensitivity: 405 nm (120 mW), 
488 nm (200 mW), 561 nm (200 mW), and 642 nm (150 mW). Upon 
each start-up, the instrument calibration tool ASSIST® was performed 
to optimize performance and consistency. Two channels (Ch01 and 
Ch09) were set to brightfield (BF), permitting spatial coordination be-
tween cameras. Channel 12 was set to side-scatter (SSC), and further 
fluorescence channels were used for antibody detection as required. 
To avoid the risk of coincident particle detection, sEV samples were 
not run at concentrations greater than 1010 objects/mL.22 sEV labe-
ling was performed as previously described.13,22-24 Briefly, fPBS diluted 
sEV sample was incubated with Fc receptor blocker (Human TruStain 
FcXTM, BioLegend, San Diego, CA) for 10 minutes at room temperature. 
The pan-EV label 5-(and-6-)-carboxyfluorescein diacetate succinimidyl 
ester (CFDA-SE, ThermoFisher) was added at a concentration of 10 μM 
and incubated in the dark for 10 minutes at 4°C. This was followed 
by further staining in the dark at room temperature for 15 minutes 
with master-mix preparations of the following monoclonal antibod-
ies (mAbs) as appropriate: anti-human CD63-PE (BioLegend, H5C6); 
PD-L1-BV605 (Biolegend, 29E.2A3); IgG1 (BioLegend, MOPC-21); 
IgG2b (BioLegend, MPC-11); HLA-B7/27-APC (MACS); HLA-A3-APC 
(eBioscience, San Diego, CA); HLA-A2-APC (Biolegend); HLA-A2-
PECy7 (Biolegend); HLA-A2-PE (BD Biosciences, San Jose, CA); HLA-
B8-APC (MACS); HLA-A24-FITC (MBL); HLA-A1-Biotin (OneLambda, 
Canoga Park, CA); HLA-A11-Biotin (OneLambda); HLA-A26-Biotin 
(OneLambda). All mAbs were centrifuged at 5000 g for 5 minutes prior 
to use, as clumps could be mistaken for EVs.25,26 To avoid false positive 
events, all antibodies used were run on ISx in buffer (fPBS) alone to en-
sure antibody clumps were not present. Technical controls and isotype 
controls, in conjunction with fluorescence-minus-one (FMO) controls, 
were employed where appropriate for EV gating. All samples were ac-
quired using INSPIRE® software. Data analyses were performed, and 
spectral compensation matrices produced, using ISx Data Exploration 
and Analysis Software (IDEAS®).
2.4 | PBMC analyses by ImageStreamx
PBMCs were incubated with viability dye-v450 (eBioscience); ac-
cording to manufacturer's instructions, and Fc receptor block was 
performed (Human TruStain FcXTM, BioLegend). For surface stain-
ing, cells were incubated for 20 minutes at 4°C with different 
combinations of the following antibodies: CD63-PE7 (BioLegend), 
PD-L1-BV605 (BioLegend), and appropriate HLA antibodies among 
those described. Following staining cells were fixed in fixation buffer 
(BioLegend). Whole-cell image acquisition was performed with fluid-
ics set at low speed, sensitivity set to high, magnification at 60x, and 
SSC and BF channels set as above. Live cells were identified after 
sequential gating for (1) single cells, using BF aspect ratio vs Area 
Feature gating; (2) in focus cells, using BF gradient root mean square 
(RMS) Feature; and (3) LIVE/DEADTM-stain negative cells (Ch02). 
Colocalization analyses were performed using the Similarity Bright 
Detail Score (SBDS) feature in IDEAS® as previously described.13,27-29 
ISx enables quantitative analysis of the degree of colocalization be-
tween fluorophores on a pixel-by pixel basis by comparing digital im-
ages captured in each of its image detection channels. The Similarity 
Bright Detail R3 algorithm within IDEAS® produces a score (SBDS) 
serving as a measure of the degree of colocalization between these.
2.5 | PBMC analyses by conventional 
flow cytometry
PBMCs were incubated with LIVE/DEADTM-APC (ThermoFisher 
Scientific) according to manufacturer's instructions, and treated 
with Fc receptor blocker (Human TruStain FcXTM, BioLegend). For 
surface staining, cells were incubated for 20 minutes at 4°C with 
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different combinations of the following fluorochrome conjugated 
antibodies: CD19-BV711, CD3-BV605, HLA-DR-BV785, CD123-PE-
Dazzle, CD11c-PE, CD16-PerCP-Cy5.5 (BioLegend); Viability-V450, 
CD14-AF780 (eBioscience); and appropriate HLA antibodies. 
Following staining cells were fixed in fixation buffer (BioLegend). 
Conventional flow cytometry was performed using LSR Fortessa 
flow cytometer (BD) and analyzed using FlowJo software v7.6 (Tree 
Star,Ashland, OR).
2.6 | Generation of monocyte-derived dendritic 
cells (DCs)
Monocytes from HLA-A2 negative healthy volunteers were isolated 
from PBMCs using the EasySepTM Human CD14 positive selection 
kit (Stemcell Technologies, Vancouver, BC). Monocyte-derived DCs 
were generated by culturing freshly isolated monocytes for 5 days in 
EV-free complete media with 50 ng/mL of granulocyte-macrophage 
colony-stimulation factor (GM-CSF) and 800 U/mL IL-4 (R&D 
Systems, Minneapolis, MN), at 37°C in 5% CO2. Following 5 days 
of culture, cells were harvested, washed, and cultured for a further 
48 hours with a cytokine cocktail of GM-CSF (50 ng/mL), interleu-
kin-4 (IL-4; 800 U/mL), tumor necrosis factor alpha (TNFα; 10 ng/mL), 
IL-6 (10 ng/mL), IL-1β (10 ng/mL), and prostaglandin E2 (1 μg/mL, all 
from R&D Systems) to induce DC maturation.30 DCs generation was 
confirmed by flow cytometric analysis of the expression of surface 
markers assessed at days 0, 5, and 7 using the following conjugated 
antibodies: CD14-V450, CD40-APCCy7, CD1a-BV605, CCR7-BV711, 
HLA-DR-PerCPCy5, CD80-FITC, CD86-PE (Figure S2).
2.7 | Cross-dressing of monocyte-derived DC and 
CD8 T cell proliferation assays
Monocyte-derived DCs were co-cultured for 24 hours in serum-free 
media (X-VIVOTM 15, Lonza, Basel, Switzerland) with sEVs freshly 
isolated as described previously from HLA-A2 positive and HLA-
A2 negative healthy volunteers; 5 x 105 DCs were co-cultured with 
50 μl sEV isolate, and successful cross-dressing of DCs confirmed 
by flow cytometric analysis of HLA-A2 (Figure 4A-B). This approach 
achieves consistent cellular cross-dressing, as we have previously 
described.13 Harvested DCs were immediately cultured for a further 
5 days with 105 CD8 T cells at a 1:1 or 1:2 ratio. CD8 T cells were 
isolated from PBMCs from HLA-A2 negative and HLA-A2 positive 
healthy controls using the EasySep™ Human CD8 + T Cell Isolation 
Kit (Stemcell Technologies). To detect T cell proliferation, isolated 
CD8 T cells were incubated with eFluorTM 670 proliferation dye 
(eBioscience) for 20 minutes in the dark at room temperature and 
then washed and counted. At the end of co-culture, CD8 prolifera-
tion was quantified by flow cytometry. In order to determine the 
role of human sEVs in allostimulation, equivalent experiments were 
conducted employing circulating sEVs isolated from kidney and liver 
transplant recipients pretransplant and at days 1 and 10 following 
transplantation. To investigate whether cross-dressing with sEVs 
isolated from transplant recipients modifies the phenotype and 
cytokine production of DCs, we cultured for 24 hours DCs derived 
from healthy individuals’ monocytes with sEVs isolated from either 
healthy individuals, liver transplant recipients, or kidney transplant 
recipients (at day 1 and day 10 posttransplant), and (1) used flow 
cytometry to analyze the changes in the expression of costimulatory 
molecules (CD40, CD86) and PD-L1; and (2) quantified IL-6 and IL-10 
levels in culture supernatants using Human IL-6 and Human IL-10 
ELISA MAX™ kits (Biolegend, London, UK) according to manufac-
turer's instructions. For ELISA experiments, supernatant of DCs cul-
tured for 24 hours with or without sEVs were thawed on ice prior to 
use and diluted 1:10 for IL-6 and 1:2 for IL-10; analysis of standards 
and samples was carried out in duplicate; and plates were read at 
450 nm and values extrapolated from a 5-parameter curve.
2.8 | Statistical analysis
Statistical analyses were performed by GraphPad Prism v7.0 
Software. Student's t and Mann-Whitney tests were used for com-
parisons between two groups as appropriate, and analysis of vari-
ance (ANOVA; with Tukey's posttest) to compare more than two 
groups. Paired samples were compared by nonparametric Wilcoxon 
tests (*P < .05, **P < .01, ***P < .001, and ****P < .0001).
3  | RESULTS
3.1 | Host cells cross-dressed with donor HLA 
molecules are highly prevalent following liver 
transplantation
In order to evaluate the presence of cross-dressed recipient cells fol-
lowing liver transplantation, we enrolled 8 liver and 3 kidney trans-
plant recipients who exhibited HLA class I mismatches amenable 
to discrimination using available fluorescent anti-HLA antibodies 
(Table 1). Conventional flow cytometry was used to assess the pres-
ence of circulating passenger leukocytes (displaying donor- but not 
recipient HLA) and cross-dressed recipient cells (displaying both 
donor- and recipient HLA) following kidney and liver transplantation. 
Monocytic, dendritic, T cell, and B cell subsets were specifically ana-
lyzed (Figure 1A). Although circulating cross-dressed cells were noted 
to be present in all 8 liver transplant recipients analyzed, only 5 ex-
hibited detectable levels of passenger leukocytes. Both cross-dressed 
and passenger leukocyte numbers peaked in the first 24 hours fol-
lowing liver transplantation, with their number waning to negligible 
levels by postoperative day 30 (Figure 1B). By day 30 postoperatively, 
only 2 liver transplant recipients were found to have detectable levels 
of cross-dressed cells, and none had detectable levels of passenger 
leukocytes in circulation. Neither cross-dressed nor passenger leu-
kocytes were detectable in the circulation of subjects having under-
gone kidney transplantation throughout the duration of follow-up 
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(Figure 1B). On subset analysis, CD14 + monocytes formed the bulk 
of cross-dressed cells (Figure 1B, left panels), and passenger leuko-
cytes were made up of varying proportions of cells across the whole 
spectrum of immune cell subsets analyzed (Figure 1B, right panels), 
but their overall numbers were significantly lower than those of cross-
dressed cells (Figure 1C). Advanced imaging flow cytometry was per-
formed by ImageStreamx in order to achieve visual corroboration of 
the cross-dressing of recipient APCs with donor HLA molecules. As 
compared to recipient HLA, which is diffusely present, donor HLA was 
seen as discrete spots on the recipient cell, a pattern in keeping with 
our previously published in vitro analyses of sEV uptake kinetics.13
3.2 | Circulating sEVs bearing donor HLA peak 
early following liver transplantation and are no longer 
detectable at late time points after transplantation
Next, we investigated whether circulating EVs of donor origin could 
be detected following liver or kidney transplantation. To do this, 
we used advanced imaging flow cytometry – an approach that al-
lows sensitive multiparameter characterization of nanosized parti-
cles.13,22,23 Small EVs were isolated from plasma by size-exclusion 
chromatography as previously described (Figure S2). SEC offers sig-
nificant advantages over alternative methods of sEV isolation. These 
include a reduced risk of sEV damage during isolation, relatively 
low co-precipitation of nonvesicular contaminants, the capacity 
to extract sEVs from low-volume clinical samples, and the reduc-
tion of user-variability through the use of commercial SEC columns. 
Although no single marker can serve to uniquely identify exosomes, 
comprehensive proteomic analyses of sEV subtypes identified CD63 
as among the most suitable.14 Thus, isolated sEVs bearing exosomal 
marker CD63 (putative exosomes) were assessed for their expres-
sion of donor HLA (Figure 2A,B). Circulating CD63 + sEVs bear-
ing donor HLA were identified in all 8 liver transplant recipients in 
the early posttransplant period, with a peak at postoperative day 
1, though falling to undetectable levels by day 4 posttransplant 
(Figure 2C). The peak in donor sEV number corresponded with the 
peak in cross-dressed circulating leukocytes in liver transplant re-
cipients. No circulating donor sEVs were detectable in any kidney 
transplant recipients investigated, which also corresponded to the 
absence of cross-dressed cells detectable in these patients.
3.3 | Circulating sEVs bearing donor 
HLA are not detected in recipients undergoing 
allograft dysfunction due to rejection at late time 
points posttransplant
To determine whether donor sEVs release can be detected in cir-

















































































Abbreviations: ESRD, end-stage renal disease; HCC, hepatocellular carcinoma; HCV, hepatitis C 
virus; HHT, hereditary hemorrhagic telangiectasia; NASH, nonalcoholic fatty liver disease; POD, 
postoperative day; PSC, primary sclerosing cholangitis.
TA B L E  1   Clinical characteristics and 
HLA-type of transplant recipients
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F I G U R E  1   Circulating cross-dressed leukocyte subsets peak early following liver transplantation. (A) Gating strategy for the 
identification of CD19 + B cells, CD14 + monocytes, CD11c + dendritic cells, and CD3 + T cells (CD: cross-dressed; PL: passenger 
leukocytes). (B) Distribution of cross-dressed (left) and passenger (right) leukocyte subsets pre- and 1, 4, 10, and 30 days post- liver (n = 8) or 
kidney (n = 3) transplantation. Analysis of variance with Tukey's posttest highlighted significance relative to PRE time point. (C) Differential 
percentages of circulating cross-dressed and passenger leukocytes in liver recipients 1 day after transplantation. Wilcoxon paired test. (D) 
Analysis by advanced imaging flow cytometry (ImageStreamx) of recipient (recipient HLA+, red) circulating cells cross-dressed with donor 
HLA (yellow) observed as characteristically discrete spots. Each cell image is representative of 1 of 8 liver transplant recipients analyzed. 
(*P < .05, **P < .01)
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immediate posttransplant period, we conducted circulating sEV anal-
yses on sequential plasma samples collected from liver transplant 
recipients experiencing biopsy-proven T cell–mediated rejection 
following an attempt at complete immunosuppression withdrawal. 
These rejection episodes were, on average, seven and a half years 
following transplantation (range: 4.9-10.5 years). In contrast to the 
very consistent release of donor sEVs observed shortly after liver 
transplantation, no significant rise in sEVs bearing donor HLA was 
noted before or at the time of rejection in this context (Figure 2E, 
and Table S1).
F I G U R E  2   Circulating donor-derived CD63 + small extracellular vesicles (sEVs) bearing PD-L1 peak early following liver transplantation 
(LTx). Advanced imaging flow cytometry was used for the multiparametric analysis of sEVs using Amnis ImageStreamx (ISx). (A) Polystyrene 
calibration beads of known size demonstrate the capacity for small particle acquisition by ISx. Speed beads and their aggregates serve as 
internal calibrators for the cytometer and the fluidics system (left panel). Gating of CFDA-SE-labeled small EVs including exosomes (right 
panel) was performed with reference to fluorescently labelled liposomes of known size and displaying scatter characteristics resembling 
exosomes (middle panel). Representative plots modified with permission from Mastoridis et al.13 (B) Gated small EVs were further analysed 
for the expression of exosomal marker CD63 and donor HLA, and double-positive events then interrogated for the presence of programmed 
death ligand 1 (PD-L1). Representative plots modified with permission from Mastoridis et al.13 (C) The kinetics of donor sEV (d-sEVs: 
CD63 + donor HLA+) release into the circulation in the peritransplant period in both liver and kidney allograft recipients were compared to 
the presence of cross-dressed cells in circulation (ascertained by conventional flow cytometry, see Figure 1; ANOVA with Tukey's posttest, 
significance indicated relative to PRE timepoint). (D) The expression of programmed death ligand 1 (PD-L1) on sEVs of donor and recipient 
origin were compared among liver transplant recipients. (E) Liver allograft rejection following immunosuppression withdrawal is not 
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3.4 | sEVs of donor origin are enriched in PD-L1 that 
is transferred in tandem with donor HLA to cross-
dressed recipient cells
The intrahepatic expression of PD-L1 is upregulated following liver 
transplantation in both mice and humans and has been implicated 
in the regulation of alloimmune responses and the establishment of 
liver allograft tolerance.18,31,32 We observed that a higher proportion 
of circulating donor-derived sEVs carried membrane-bound PD-L1 
than sEVs of recipient origin (Figure 2B,D). Likewise, recipient cross-
dressed cells (ie, displaying donor HLA molecules in their membrane) 
expressed higher PD-L1 than recipient cells not bearing donor HLA 
(Figure 3A,B), in keeping with what has been previously described 
in a murine liver transplant model.18 To determine whether PD-L1 
on recipient cross-dressed cells is transferred in tandem with donor 
HLA, we conducted colocalization analyses by ISx using SBDS scor-
ing. PD-L1 colocalized with donor HLA, suggesting that the elevated 
PD-L1 expression observed on cross-dressed cells may be due to 
tandem transfer on donor-derived sEVs (Figure 3A,C). In contrast, 
donor HLA did not colocalize with the exosomal marker CD63 (data 
not shown), likely reflecting the fact that CD63 is borne by both 
donor and recipient sEVs alike but also the possibility that donor 
HLA may also be derived by non-sEV-dependent pathways such as 
cell-cell contact and cell nibbling.
3.5 | sEVs derived from liver but not kidney 
recipients transiently inhibit allogenic T cell responses
We sought to investigate the extent to which cross-dressing influences 
human APC immunogenicity, both in healthy individuals and in the set-
ting of clinical transplantation. First, we employed HLA-A2 negative 
monocyte-derived dendritic cells (DCs) from healthy individuals that 
had been cross-dressed in vitro with plasma-derived HLA-A2 posi-
tive sEVs harvested from an allogeneic healthy control (Figure 4A,B). 
Following culture with allogeneic sEVs, DCs displayed HLA-A2 expres-
sion on their surface and acquired the capacity to elicit proliferation of 
syngeneic CD8 + T cells (Figure 4C). Next, we conducted experiments 
in which monocyte-derived DCs from healthy controls were cultured 
for 24 hours with plasma-derived sEVs harvested from allogeneic 
liver (n = 7) and kidney (n = 3) recipients on days 1 and 10 posttrans-
plant. DCs were then washed and replated for 5 days with allogeneic 
third-party CD8 T cells. sEVs isolated on day 2 post–livertransplanta-
tion (Figure 5A), but not those harvested from day 1 kidney recipients 
(Figure 5B), significantly inhibited T cell proliferation (7.4% ± 3.1% 
vs 22.4% ± 2.4% as compared to non-cross-dressed DCs; P < .001; 
Figure 5A). The inhibition of CD8 T cell proliferation observed when 
employing day 1 liver transplant recipient sEVs was reduced when DCs 
were cultured with day 10 sEVs, although the effect was still significant 
in comparison with non-cross-dressed DCS (Figure 5A). In contrast, 
circulating sEVs from kidney transplant recipients did not induce sig-
nificant changes in third-party CD8 T cell responses (Figure 5B). To 
investigate the effect of sEVs isolated from liver transplant patients on 
DCs, we analyzed the changes in the expression of costimulatory mol-
ecules (CD40 and CD86) in DCs cultured with sEVs for 24 hours. DCs 
cultured with sEVs isolated from liver transplant recipients at day 1 
following transplantation expressed significantly less CD40 than DCs 
cultured with sEVs at day 10 (P = .005), or DCs without sEVs. This was 
not observed in kidney transplant recipients (Figure S3A). In addition, 
DCs cultured with sEVs from liver transplant recipients produced less 
IL-6 and more IL-10 when compared to the use of sEVs from kidney 
transplant recipients (Figure S3B). Altogether, these data suggest that 
sEVs from liver transplant patients have a heightened capacity to in-
duce an inhibitory phenotype in DCs.
F I G U R E  3   Cross-dressed recipient 
cells are enriched in programmed death 
ligand 1 (PD-L1), and this colocalizes 
with donor HLA molecules. Analysis of 
circulating peripheral blood mononuclear 
cells (PBMCs) by imaging flow cytometry 
of liver transplant recipients 1-day 
posttransplant. (A) Representative profiles 
of CD14 + recipient cells cross-dressed 
with donor HLA. The antibodies used are 
indicated at the top of each column. (B) 
PD-L1 expression in recipient and cross-
dressed cells (n = 8). (C) Colocalization 
analysis of PD-L1 with recipient or donor 
HLA molecules by Bright Detail Similarity 






































































     |  9MASTORIDIS eT Al.
4  | DISCUSSION
In the context of transplantation, T cells can be activated through 
the direct, indirect, and semidirect allorecognition pathways. The 
semidirect pathway, which involves the activation of directly al-
loreactive T cells upon recognition of intact donor MHC molecules 
presented by recipient APCs, was originally proposed as a con-
ceptual solution to the “three cell model” conundrum, that is, the 
need for recipient CD4 + T cells to recognize donor allopeptides 
on the same APCs directly presenting intact donor MHC mole-
cules to alloreactive CD8 + cells, in order for CD4 + subsets to be 
capable of regulating alloreactive CD8 + T cells.16 Recent studies 
in experimental models indicate that the semidirect allopresenta-
tion elicited by the release of donor allograft-derived small EVs 
is indeed key in initiating and sustaining alloimmune responses. 
Thus, in skin, heart, kidney, and islet murine transplant models 
the cross-dressing of recipient APCs by EV-mediated delivery 
of intact donor MHC in secondary lymphoid tissues and/or the 
graft, and not direct allopresentation by allograft-derived APCs, 
is the main pathway through which directly alloractive T cells are 
activated.1,3,17,33
In the current study we sought to investigate whether, and in 
which circumstances, cross-dressing of recipient APCs occurs in 
clinical transplantation and the extent to which it might contribute 
to allopresentation. We provide for the first time evidence indicating 
that cross-dressed recipient leukocytes can be found in the circulation 
following liver transplantation, albeit transiently, and that their num-
bers significantly exceed those of circulating passenger leukocytes. 
This is in keeping with the observations made in the animal transplant 
models referenced previously, wherein cross-dressed recipient-type 
cells make up the majority of DCs presenting donor MHC molecule 
both in the graft and the secondary lymphoid tissue. Thus, in mice, 
shortly after liver and kidney transplantation 60% and >70% of intra-
graft DCs respectively were found to be cross-dressed,17,18 whereas 
following heart transplantation, the number of splenic APCs carry-
ing donor MHC molecules was 100-fold greater than the number of 
donor DCs that had migrated to the spleen.1 Of note, the number of 
cross-dressed APCs described in these murine models is substantially 
greater than what we observed in the circulation of human liver recipi-
ents. Furthermore, in contrast to liver, following kidney transplantation 
we detected no cross-dressed cells or passenger leukocytes, and even 
after liver transplantation the number of circulating cross-dressed cells 
rapidly waned and became undetectable by day 30 posttransplant. 
This likely reflects the limitations of being restricted to the analysis of 
blood specimens and we speculate that, as shown in murine models, 
following clinical organ transplantation recipient APC cross-dressing 
F I G U R E  4   Dendritic cells cross-
dressed with allogenic small extracellular 
vesicles (sEVs) induce T cell proliferation 
in vitro. (A) Representative profiles of 
change in HLA-A2 expression in HLA-A2 
negative cells following 24 hours co-
culture with increasing quantities of 
HLA-A2 positive (allogenic) sEVs. (B) 
Summary of 3 independent experiments 
showing increase in HLA-A2 expression 
in monocyte-derived dendritic cells 
following co-culture with HLA-A2 positive 
sEVs. (C) HLA-A2 negative monocyte-
derived dendritic cells were cross-dressed 
with either HLA-A2 positive or HLA-A2 
negative sEVs, and their capacity to 
affect CD8 T cells proliferation compared 
using flow cytometry (4 independent 
experiments; Student's t test, mean ± SD, 
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continues to occur in the allograft and/or secondary lymphoid tissues 
for prolonged periods of time. This is supported by the demonstration 
that in longstanding kidney transplant recipients with poor graft func-
tion not only indirectly but also directly primed alloreactive T cells per-
sist in the circulation.34
The mechanistic basis for APC cross-dressing is an area of on-
going research. Analyses by immunoelectron microscopy following 
murine cardiac transplantation have shown recipient DCs to acquire 
intact donor MHC molecules in graft-draining lymphoid organs by 
capturing clusters of donor-derived sEVs.1 Our data suggest that this 
is likely to be the case in humans as well. First, because the presence 
of circulating cross-dressed cells in the early posttransplant period 
coincides with a rise in circulating allograft-derived sEVs bearing 
donor HLA. Second, because in circulating cross-dressed cells donor 
HLA colocalizes with PD-L1, a molecule that is enriched in liver al-
lograft-derived sEVs. Nevertheless, the contribution of other mech-
anisms to the transfer of donor HLA molecules (eg, trogocytosis, 
or cell nibbling, either following graft infiltration by recipient cells 
or in association with passenger leukocytes35) cannot be excluded. 
The fact that we observe that not all donor HLA colocalizes with 
CD63 might offer limited support to the notion that such alternative 
mechanisms of transfer are also at play. However, this absence of 
observed colocalization, in addition to the finding that not all PD-L1 
colocalizes with donor HLA, should also be understood with the fol-
lowing considerations in mind. First, it is unlikely that all sEVs bear-
ing the particular donor HLA subtype analyzed will also carry PD-L1 
or CD63 and vice versa. Second, there are nongraft sources of PD-
L1, as well as nongraft sEVs bearing CD63. Third, target-cell intrinsic 
PD-L1 expression will not necessarily bear any spatial relation to, for 
instance, donor HLA or CD63. Finally, we have little understanding 
of the potential for variability in the cycling of different sEV constit-
uent proteins by target cells and the impact of this on the probability 
of concurrent detection.
sEVs are prone to rapid systemic dilution and clearance, pre-
dominantly by the reticuloendothelial system. Such clearance 
might account for the rapid diminution of donor-derived sEVs 
we observed following liver transplantation. There have been no 
studies assessing whether different transplanted organs release 
differing quantities of HLA-bearing sEVs, but our observations in-
dicating that in humans much fewer sEVs find their way into the 
systemic circulation after kidney than after liver transplantation 
suggest that the size of the organ and/or its particular cytoarchi-
tecture and vascular anatomy influence the quantity of sEVs being 
released.
Beyond quantitative differences among transplanted or-
gans, qualitative variation in sEVs – that is, in the repertoire 
of surface molecules and cargo that they contain – may also 
affect downstream functional outcomes. This has been clearly 
demonstrated in animal models. Thus, in a murine liver trans-
plant model, graft-infiltrating DCs cross-dressed by donor sEVs 
expressed high levels of PD-L1 and markedly suppressed do-
nor-reactive CD8 + T cell proliferative responses by inducing an 
exhausted phenotype.18 In contrast, cross-dressed DCs isolated 
from the lymphoid tissues of heart recipients failed to increase 
PD-L1 expression and promoted proliferation of directly allo-
reactive CD8 + T cells.1 Likewise, in a kidney transplant model, 
F I G U R E  5   Small extracellular vesicles (sEVs) derived from liver but not kidney transplant recipients transiently inhibit allogenic T cell 
responses. Dendritic cells (DCs) were cross-dressed with sEVs isolated from liver (n = 7) and kidney (n = 3) transplant recipients isolated 
pretransplant (Pre-Tx), and at postoperative days 1 (D1) and 10 (D10), as well as from healthy control subjects (HC). (A) DCs cross-dressed 
with sEVs harvested from liver transplant recipients on D1 and D10 posttransplant significantly inhibited third-party CD8 T cell proliferation 
as compared to non-cross-dressed DCs or DCs cross-dressed with syngeneic sEVs. (B) DCs cross-dressed with sEVs harvested from kidney 
recipients on D1 and D10 posttransplant did not significantly influence third-party CD8 T cell proliferation (paired and unpaired Student's t 
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cross-dressed DCs sustained the effector function of alloreac-
tive CD8 + T cells and induced acute and chronic rejection.17 
Our findings employing control DCs cross-dressed in vitro with 
sEVs sequentially collected from both kidney and liver human 
recipients confirm the unique inhibitory properties of the sEVs 
released after liver transplantation. This is an important obser-
vation that could mechanistically underpin the reduced immu-
nogenicity of liver allografts described both in animal models 
and in the clinic. Of note, the capacity of circulating sEVs har-
vested from liver recipients to inhibit CD8 + T cell prolifera-
tion decreased with time, in keeping with the temporal changes 
in circulating donor-derived sEVs release observed after liver 
transplantation. Whether the inhibitory effect persists in 
the liver graft itself for longer periods of time remains to be 
established.
In summary, we have described for the first time the kinetics 
of allograft-derived sEV release and circulating cell cross-dressing 
in human kidney and liver transplantation. Despite the limitation 
of being restricted to blood specimens, our data confirm several 
observations made in experimental animal models, in particular 
the clear preeminence of recipient cross-dressed cells over donor 
passenger leukocytes as a potential source for allostimulation and 
the unique downstream functional effects mediated by liver-de-
rived sEVs.
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